Compare Innodata Inc (INOD) vs Organon & Co. Common Stock (OGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Innodata Inc vs Organon & Co. Common Stock — how do they compare? Innodata Inc trades at $51.7 (market cap $1.83B), while Organon & Co. Common Stock trades at $13.73 (market cap $3.61B). The key difference: Organon & Co. Common Stock is the larger of the two by market cap, and Organon & Co. Common Stock pays a 0.58% dividend while Innodata Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Innodata Inc for 20 Days and Organon & Co. Common Stock for 0 Days on average.
| INOD | OGN | |
|---|---|---|
Market Cap | $1.83B | $3.61B |
Volume | 1,414,750 | 1,808,049 |
Sector | Technology | Health |
52-Week High | $121.50 | $13.81 |
52-Week Low | $34.45 | $5.70 |
Typical Hold Time | 20 Days | 0 Days |
Enterprise Value | $1.58B | $11.03B |
Dividend Yield | — | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INOD trades at $58.38, down 2.55% today amid a bearish technical signal despite strong fundamental performance. The company delivered three consecutive quarterly earnings beats with Q1 2026 EPS of $0.42 versus $0.13 expected, while revenue grew to $317 million in 2026 with expanding profit margins. Recent developments include the opening of a motion-capture AI lab and board appointment of former NSA director Michael Rogers, positioning the company for growth in AI infrastructure services.
The outlook remains positive given strong earnings momentum and AI sector tailwinds, though premium valuation (P/E 41.19) and technical weakness present near-term risks. Analyst consensus is bullish with 67% buy ratings, but investors should monitor customer concentration and competitive pressures in the rapidly evolving AI services market.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Innodata Inc
Innodata is a global data engineering company that provides solutions for training AI models. It helps enterprises solve complex data challenges through high-quality data annotation and digital transformation.
Read more on INOD →About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →
